New contraceptive device under attack:
This article was originally published in Clinica
Unipath has admitted that around 450 women have become pregnant while using the company's Persona contraceptive device, hailed as a rival to the pill at its launch last September 30th. The device, which has been bought by more than 100,000 women from Boots chemists, measures hormone levels in urine to establish when a woman is fertile (see Clinica No 726, p 17). Unipath has recently reduced its claimed success rate for Persona from 95% to 94%, it told the BBC's Watchdog Healthcare programme. Clinica estimates the failure rate at 1.8%.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.